Improvement of efficacy in Crohn's disease by early use of infliximab

Improvement of efficacy in Crohn's disease by early use of infliximab - Early use of infliximab in Crohn's disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020335

Enrollment

100

Registered

2015-12-30

Start date

2003-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Newly diagnosed or relapsed Crohn's disease who is naive to biologics

Exclusion criteria

Exclusion criteria: Patient who was initially treated by steroid or immunosuppressants

Design outcomes

Primary

Measure	Time frame
Improvement of long-term relapse-free rate (At 5 years after induction of remission)	—

Secondary

Measure	Time frame
Remission rate at 6 weeks after the initiation of treatment	—

Countries

Japan

Contacts

Public ContactTsuyoshi Kudo

Akita city Hospital General Administration Division

ro-homn@city.akita.akita.jp0188234171

Outcome results